Shopping Cart
- Remove All
- Your shopping cart is currently empty
RLX (PD 139530) is a PI3K/Akt/FoxO3a signal inhibitor with anticancer activity against tumour cell lines such as colon cancer, inducing sub-G1 arrest and mitochondrial potential loss, thereby inhibiting tumour growth. RLX also exhibits antitussive and anti-asthmatic activity, reducing eosinophils and total lymphocytes in bronchoalveolar lavage (BAL) fluid, and exhibits toxicity toward A549 cells.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $293 | In Stock | |
5 mg | $722 | In Stock | |
10 mg | $987 | In Stock | |
25 mg | $1,520 | In Stock | |
50 mg | $1,980 | In Stock | |
100 mg | $2,500 | In Stock |
Description | RLX (PD 139530) is a PI3K/Akt/FoxO3a signal inhibitor with anticancer activity against tumour cell lines such as colon cancer, inducing sub-G1 arrest and mitochondrial potential loss, thereby inhibiting tumour growth. RLX also exhibits antitussive and anti-asthmatic activity, reducing eosinophils and total lymphocytes in bronchoalveolar lavage (BAL) fluid, and exhibits toxicity toward A549 cells. |
Alias | THA-Q, THA Q, PD-139530, PD139530, PD 139530 |
Molecular Weight | 214.26 |
Formula | C13H14N2O |
Cas No. | 4425-23-4 |
Smiles | O=C1C=2C=CC=CC2N=C3N1CCCCC3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.